Lulu Xue | Drug | Innovative Research Award

Innovative Research Award

Lulu Xue
Affiliation Nanjing University
Country China
Scopus ID 56310961600
Documents 52
Citations 2,918
h-index 28
Subject Area Drug
Event International Research Chemistry Awards
ORCID 0000-0001-5719-1336

Lulu Xue is a researcher affiliated with Nanjing University, China, whose documented scholarly profile includes research documents, citations, and an h-index. The profile identifies Drug as the principal subject area. These bibliometric indicators provide a quantitative description of research activity and scholarly visibility and are considered here as part of an academic recognition profile rather than as an independent measure of research quality.[1]

Abstract

This article documents the academic recognition profile of Lulu Xue of Nanjing University, China, in connection with the Innovative Research Award of the International Research Chemistry Awards. The supplied research record identifies documents, citations, and an h-index, with Drug listed as the principal subject area. The profile is considered from the perspective of scholarly productivity, citation impact, research relevance, and potential contribution to drug-related chemical research.[1]

Keywords

Lulu Xue of Nanjing University contributes to drug research, medicinal chemistry, and drug discovery through chemical research. Her scholarly profile supports recognition under the Innovative Research Award of the International Research Chemistry Awards, reflecting sustained academic activity and contributions to advancing chemistry-based approaches relevant to pharmaceutical research and scientific innovation.[1]

Introduction

Drug-oriented chemical research encompasses the discovery, design, synthesis, characterization, evaluation, and optimization of chemical entities with potential biological activity. Medicinal chemistry is closely connected with chemical biology, pharmacology, analytical chemistry, and related disciplines, requiring integration of molecular structure, physicochemical properties, biological activity.[2]

Research Profile

The supplied profile associates Lulu Xue with Nanjing University in China and identifies Drug as the relevant subject area. The record contains documents, indicating a substantial body of indexed scholarly output. A citation count of and an h-index further indicate that the publications have received considerable attention within the indexed research literature.[2]

Research Contributions

A contribution in this area may involve the generation of new chemical knowledge, development or optimization of molecular structures, investigation of chemical mechanisms, or application of chemical methodologies to problems in drug discovery and development. Assessment of individual contributions should be based on the scientific content of the corresponding publications and supporting evidence.[3]

Publications

The supplied profile records documents for Lulu Xue. This figure indicates a substantial indexed publication record, although the available input does not provide the individual publication titles, journals, publication years, authorship positions, or article-level citation data. Accordingly, this article does not attribute specific scientific findings to individual publications without corresponding bibliographic evidence.[4]

Research Impact

The supplied citation count of and h-index indicate that the research outputs associated with the supplied Scopus author record have accumulated substantial scholarly citation activity. Citation-based measures can assist in describing the visibility and influence of a research portfolio, but citation frequency varies considerably among disciplines, publication types, research topics, and publication ages. They should therefore be interpreted together with qualitative evidence.[2]

Award Suitability

Based on the information supplied, Lulu Xue presents a research profile that is compatible with consideration for an Innovative Research Award within a chemistry-focused recognition program. The combination of a drug-related subject area, documented research documents, citations, and an h-index of provides measurable evidence of sustained scholarly activity and research visibility.[3]

Conclusion

Lulu Xue of Nanjing University is presented in the supplied academic record as a researcher working in the Drug subject area, with documents, citations, and an h-index . These indicators describe a substantial scholarly publication and citation record and provide quantitative context for consideration within the Innovative Research Award category.[4]

References

    1. Elsevier. (n.d.). Scopus author details: Lulu Xue, Author ID 56310961600. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=56310961600
    2. ORCID. (n.d.). ORCID record: Lulu Xue, ORCID iD 0000-0001-5719-1336. ORCID.
      https://orcid.org/0000-0001-5719-1336
    3. International Research Chemistry Awards. (n.d.).
      https://researchchemistry.org
    4. Gu, Z., Xiong, X., Chen, X., Zhang, H., Gu, N., & Xue, L. (2026). Ligand-mediated reprogramming redirects liver-tropic ionizable lipid nanoparticles for lung-selective mRNA delivery. Angewandte Chemie International Edition.
      https://doi.org/10.1002/anie.6080664

Dr. Aloïse Mabondzo | drug design | Best Researcher Award

Dr. Aloïse Mabondzo | drug design | Best Researcher Award

Doctorate at CEA, France

Professional Profiles

Google Scholar

Scopus

Orcid

🎓 Educational Background

Dr. Aloïse Mabondzo, has a distinguished academic foundation. He earned his Master’s degree in Molecular and Cellular Biology from the University of Strasbourg, France (1986-1989). Driven by a passion for cutting-edge research, he pursued a PhD in Virology and Immunology at the prestigious Pierre and Marie Curie University, France (1989-1993). His doctoral work focused on Active Immunotherapy using bispecific antibodies against HIV, a testament to his early commitment to tackling global health challenges.

🧪 Professional Positions

Dr. Mabondzo’s illustrious career began with a Post-doctoral Research Fellowship (1993-1997) at the CEA Neurovirology Department, where he made significant contributions to the field of neurovirology. In 1998, he joined the CEA Medicine and Healthcare Technologies Department, where he has served as Research Director and Head of the Neurovascular Unit Research and Therapeutic Innovation Laboratory. His leadership in these roles has driven breakthroughs in neurovascular research. Since 2019, Dr. Mabondzo has also been the Co-founder and Research Director of Ceres Brain Therapeutics, a startup dedicated to pioneering therapeutic innovations.

👩‍🏫 Mentoring and Supervision

Dr. Mabondzo has a proven track record as a mentor and supervisor. Over his career, he has supervised 16 PhD candidates (10 past, 6 current), 7 Postdoctoral Fellows (4 past, 3 current), and several other researchers, including 2 Research Assistants, 2 Engineers, and 2 Technicians. His mentorship has nurtured the next generation of scientists, fostering innovation and collaboration.

Publications Top Noted📄 

Dodecyl creatine ester therapy: from promise to reality

Authors: Mabondzo, A.; van de Kamp, J.; Mercimek-Andrews, S.

Journal: Cellular and Molecular Life Sciences

Year: 2024

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Authors: Angeli, E.; Paris, J.; Le Tilly, O.; Paintaud, G.; Bousquet, G.

Journal: Experimental Hematology and Oncology

Year: 2024

Impaired brain glucose metabolism as a biomarker for evaluation of dodecyl creatine ester in creatine transporter deficiency: Insights from patient brain-derived organoids and in vivo [18F]FDG PET imaging in a mouse model

Authors: Disdier, C.; Soyer, A.; Broca-Brisson, L.; Tournier, N.; Mabondzo, A.

Journal: Neurobiology of Disease

Year: 2024

Targeting the Multiple Complex Processes of Hypoxia-Ischemia to Achieve Neuroprotection

Authors: Maïza, A.; Hamoudi, R.; Mabondzo, A.

Journal: International Journal of Molecular Sciences

Year: 2024

Epigenetic alterations in creatine transporter deficiency: a new marker for dodecyl creatine ester therapeutic efficacy monitoring

Authors: Broca-Brisson, L.; Disdier, C.; Harati, R.; Hamoudi, R.; Mabondzo, A.

Journal: Frontiers in Neuroscience

Year: 2024